269 related articles for article (PubMed ID: 24152218)
1. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
[TBL] [Abstract][Full Text] [Related]
2. Antigen Expression Varies Significantly between Molecular Subgroups of Acute Myeloid Leukemia Patients: Clinical Applicability Is Hampered by Establishment of Relevant Cutoffs.
Herborg LL; Nederby L; Brøndum RF; Hansen M; Hokland P; Roug AS
Acta Haematol; 2021; 144(3):275-284. PubMed ID: 33271547
[TBL] [Abstract][Full Text] [Related]
3. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
Al-Mawali A; Pinto AD; Al-Zadjali S
Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
[TBL] [Abstract][Full Text] [Related]
4. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.
Larsen HØ; Roug AS; Just T; Brown GD; Hokland P
Cytometry B Clin Cytom; 2012 Jan; 82(1):3-8. PubMed ID: 22173921
[TBL] [Abstract][Full Text] [Related]
5. Human myeloid inhibitory C-lectin: a highly specific and stable acute myeloid leukemia marker.
Eissa DS; Kandeel EZ; Ghareeb M
Hematol Oncol; 2017 Dec; 35(4):814-820. PubMed ID: 27734526
[TBL] [Abstract][Full Text] [Related]
6. The CLEC12A receptor marks human basophils: Potential implications for minimal residual disease detection in acute myeloid leukemia.
Toft-Petersen M; Stidsholt Roug A; Plesner T; Ebbesen L; Brown GD; Nederby L
Cytometry B Clin Cytom; 2018 May; 94(3):520-526. PubMed ID: 28718199
[TBL] [Abstract][Full Text] [Related]
7. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
[TBL] [Abstract][Full Text] [Related]
8. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
[TBL] [Abstract][Full Text] [Related]
9. A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.
Das N; Gupta R; Gupta SK; Bakhshi S; Malhotra A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A; Sharma A; Kumar L
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e673-e684. PubMed ID: 32561191
[TBL] [Abstract][Full Text] [Related]
10. ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia.
Mohd Amin A; Panneerselvan N; Md Noor S; Mohtaruddin N; Sathar J; Norbaya WS; Osman R; Kee LH; Mohd Yaakub WH; Cheong SK; Abdullah M
Malays J Pathol; 2023 Apr; 45(1):65-76. PubMed ID: 37119247
[TBL] [Abstract][Full Text] [Related]
11. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells.
Jaddaoui S; Bencharef H; Lamchahab M; Quessar A; Oukkache B
Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704721
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
[TBL] [Abstract][Full Text] [Related]
14. [Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia].
Wang YZ; Chang Y; Zhu HH; Qin YZ; Li JL; Fu JY; Li LD; Chen SS; Huang XJ; Lu DP; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):427-32. PubMed ID: 16800913
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.
Du W; Li J; Liu W; He Y; Yao J; Liu Y; Lin J; Zheng J
Tumour Biol; 2016 Mar; 37(3):3817-21. PubMed ID: 26474588
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
19. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
[TBL] [Abstract][Full Text] [Related]
20. Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome.
Toft-Petersen M; Nederby L; Kjeldsen E; Kerndrup GB; Brown GD; Hokland P; Stidsholt Roug A
Br J Haematol; 2016 Nov; 175(3):393-401. PubMed ID: 27612176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]